Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Significant progress with B7-H3 targeting radio-antibody

Thursday, October 3, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has made significant progress in its clinical development, receiving IND approval from the US FDA to initiate a Phase 1 therapeutic study targeting B7-H3 with its product BetaBart (RV-01). The company has also dosed its first patient in a Phase 1/2a clinical study. These advancements suggest a promising trajectory for the company's therapeutic programs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has received IND approval from the US FDA.
  • The company is progressing with a Phase 1/2a clinical study targeting B7-H3.
  • Positive clinical updates have been reported across four programs.

Full Press Release Details

• Announcements
• With Video
• October 3, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• October 27, 2022
• Announcements
• November 26, 2021
• Announcements
• November 15, 2023
• Announcements
• June 1, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What recent approval did Radiopharm receive?

Radiopharm Theranostics received IND approval from the US FDA.

What is the focus of the Phase 1 study?

The Phase 1 study focuses on targeting B7-H3 with BetaBart (RV-01).

What progress has been made in clinical studies?

Radiopharm has dosed its first patient in the Phase 1/2a clinical study.

How many programs have positive updates?

Radiopharm has reported positive updates across four programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics B7-H3 BetaBart clinical study FDA approval
Last updated: Oct 3, 2024